YD Bio Ltd income statement

In fiscal 2025, YD Bio Ltd reported revenue of $596,817, up 16.9% on the year before, operating income of −$5.3m (a -883.3% margin) and net income of −$8.3m, or −$0.12 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

YD Bio Ltd: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	350	510	597
Cost of revenue	197	355	429
Gross profit	153	155	167
Research and development	—	491	1,602
Selling and marketing	7	2	171
General and administrative	153	1,124	3,663
Operating income	−10	−1,462	−5,272
Interest expense	2	1	—
Income before tax	18	−1,386	−8,313
Income tax	4	25	−2
Net income	14	−1,412	−8,311
Diluted EPS	$0.00	−$0.02	−$0.12
Diluted shares (average)	65m	65m	67m
EBITDA	−7	−1,452	−5,255

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ISPC vs YDES QSI vs YDES BGLC vs YDES ACON vs YDES

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from YD Bio Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to YD Bio Ltd.